Handelsbanken Fonder AB Acquires 115,000 Shares of ACADIA Pharmaceuticals Inc. (ACAD)

Handelsbanken Fonder AB lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 54.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 325,000 shares of the biopharmaceutical company’s stock after buying an additional 115,000 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.26% of ACADIA Pharmaceuticals worth $7,303,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Earnest Partners LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $133,000. Point72 Asia Hong Kong Ltd grew its position in shares of ACADIA Pharmaceuticals by 822.9% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 4,439 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 3,958 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of ACADIA Pharmaceuticals by 104.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,562 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 5,396 shares during the period. Xact Kapitalforvaltning AB purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $335,000. Finally, BB&T Securities LLC grew its position in shares of ACADIA Pharmaceuticals by 136.0% in the 4th quarter. BB&T Securities LLC now owns 12,658 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 7,295 shares during the period. 97.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ACAD stock opened at $16.33 on Friday. ACADIA Pharmaceuticals Inc. has a one year low of $14.51 and a one year high of $41.20.



ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.12. The company had revenue of $48.90 million for the quarter, compared to the consensus estimate of $47.06 million. ACADIA Pharmaceuticals had a negative net margin of 161.44% and a negative return on equity of 71.47%. ACADIA Pharmaceuticals’s revenue for the quarter was up 219.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.72) EPS. equities analysts expect that ACADIA Pharmaceuticals Inc. will post -1.71 earnings per share for the current year.

ACAD has been the topic of a number of recent research reports. ValuEngine downgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, March 23rd. BidaskClub downgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 11th. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Tuesday, May 1st. JPMorgan Chase & Co. set a $50.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 10th. Finally, HC Wainwright reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, May 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $47.45.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply